Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

135 – Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control

By Jimmy He PharmD, DScMarch 31, 2026

…three PICs with suppressed viral load for >6.5 years (ID107), >7.5 years (ID9254) and 2.5 years (ID142) following HIV-1 broadly neutralising antibody administration.  Methods The intact/inducible proviral reservoir was quantified…

699 – Effects of Semaglutide on Subclinical Cardiovascular Health in People With HIV

By Jimmy He PharmD, DScMarch 31, 2026

…visceral adiposity, blood pressure, glucose metabolism, and lipids in PWH and lipohypertrophy. The current analysis investigates effects of semaglutide on measures of subclinical cardiovascular health. Methods Virologically-suppressed PWH without known…

Recruitment of functionally different NK cells to the rectal mucosa in vaccinated macaques

By Enthusiast Inc MDSeptember 29, 2014

Background: Increasing evidence suggest that HIV can be controlled by Natural Killer cells (NK cells), via multiple mechanisms including antibody dependent cellular cytotoxicity (ADCC). In the RV144 vaccine trial, that…

THE ROLE OF ADAPTIVE NK CELLS DURING ACUTE HIV-1 INFECTION WITH DIFFERENT SUBTYPES

By Jimmy He PharmD, DScApril 4, 2022

…NK cell ADCC responses were determined against antibody coated Raji cells. The metabolic profile was assessed by a Seahorse technology. Soluble markers were measured using multiplexed assays.The Mann–Whitney U, Wilcoxon-test,…

PERSONS LIVING WITH HIV (PLHIV) WITH ADVANCED HIV DISEASE: NEED FOR NOVEL CARE MODELS

By Enthusiast Inc MDMarch 5, 2018

…Kaplan-Meier estimators and log-rank tests. LTF after ART initiation was defined as no visit >6 months; deaths were ascertained from medical records. The combined endpoint was used as deaths are…

1286 – Effectiveness of Ceftriaxone Monotherapy for Gonorrhea Treatment

By Jimmy He PharmD, DScMarch 20, 2025

…8%. In this context, the study compares the effectiveness of CRO 1g IM monotherapy versus combination in eradicating NGIs. Methods All NGIs diagnosed at our clinic between January 2022 and…

ACTIVATION OF HIV-SPECIFIC CD8+ T CELLS FROM HIV+ DONORS BY VESATOLIMOD

By Enthusiast Inc MDMarch 7, 2019

…by leukapheresis, separated by Ficoll centrifugation, and treated with GS-9620 (20 and 1000 nM) or vehicle alone for 24 hours. HIV pentamers (Proimmune) composed of five MHC Class I peptide-complexes…

Increase in CD4 Counts at Presentation to ART Care Among Urban HIV Clinics in Uganda

By Enthusiast Inc MDFebruary 27, 2015

…– 2013, of whom 21895 (36.9%) had documented CD4 results at entry into care. Of these, 73% were women; median age was 32 years (Interquartile range: 26, 39). The median…

High Acceptability of PrePex™ Device in Routine Programmatic Settings in Rwanda

By Enthusiast Inc MDFebruary 27, 2015

Background: The PrePex™ device offers an alternative to conventional surgical methods of male circumcision. Because it does not require injectable anesthesia or the cutting of vital tissue, PrePex™ requires less…

A RANDOMIZED CONTROLLED TRIAL OF BERBERINE EFFICACY ON METABOLIC SYNDROME PLUS HIV

By Jimmy He PharmD, DScMarch 3, 2023

…to evaluate the efficacy of berberine for improving clinical features, insulin resistance, metabolic profile, and inflammatory markers. Methods: A randomized, double-blind, placebo-controlled trial was performed in adults living with HIV…

←1
23456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657
…5859606162…
6364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top